0001209191-23-038033.txt : 20230616
0001209191-23-038033.hdr.sgml : 20230616
20230616174520
ACCESSION NUMBER: 0001209191-23-038033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WINSTON ROY
CENTRAL INDEX KEY: 0001751757
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 231022515
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5401 WEST KENNEDY BOULEVARD
STREET 2: SUITE 890
CITY: TAMPA
STATE: FL
ZIP: 33609
BUSINESS PHONE: 813-553-6680
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-14
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001751757
WINSTON ROY
C/O PACIRA BIOSCIENCES, INC.
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA
FL
33609
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-06-14
4
A
0
10950
0.00
A
52306
D
Stock Option (Right to Buy)
38.74
2023-06-14
4
A
0
27500
0.00
A
2033-06-14
Common Stock
27500
27500
D
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
/s/ Kristen Williams, Attorney-in-Fact
2023-06-16